Enterprise Therapeutics Closes £26 million ($33.1 million) Series B Follow-on Financing
Round led by new investor Panakes, with participation from all existing investors Funding will support Phase 2a clinical proof of concept trial in cystic fibrosis for a novel first in class ENaC blocker (ETD001) and pipeline expansion Dr Rob Woodman, Partner at Panakes, appointed to the Board of Directors Brighton, UK, 30 January 2024: Enterprise […]